hit counter
Aldeyra Therapeutics, Inc. (ALDX) Stock News Sentiment & Price - Sentifly
ALDX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aldeyra Therapeutics, Inc. (ALDX)

USA
Biotechnology
NASDAQ
ALDX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALDX Latest news
Business Wire
Neutral
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
2021-10-21 08:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, October 28, 2021 to report financial results for the quarter ended September 30, 2021 and discuss recent business highlights. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 8891298. A live webcast of the conference call will also be available on the Investors & Media

Business Wire
Neutral
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2021-09-09 08:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer & Co. at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 9:55 a.m. ET. A live webcast of the conversation will be available

Business Wire
Neutral
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
2021-09-02 08:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences: Citi's 16th Annual BioPharma Virtual Conference Date: Thursday, September 9, 2021 Time: 8:50 a.m. ET Panel: Eyes on the Prize - Next Generation Reti

Seeking Alpha
Neutral
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript
2021-08-05 18:39

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call Transcript

Business Wire
Neutral
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
2021-08-05 07:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights. “We continue to make meaningful strides toward our goal of developing effective and highly differentiated new therapies to treat ocular and systemic diseases with significant unmet medical need,” state

Benzinga
Positive
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
2021-08-04 11:23

The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a methotrexate for intravitreal injection.

Business Wire
Neutral
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
2021-08-04 08:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). There are no approved drug treatments for patients with RP, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. The disease affects an estimated 82,000-110,00

Business Wire
Neutral
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
2021-08-03 08:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the BTIG Virtual Biotechnology Conference and the H.C. Wainwright Ophthalmology Virtual Conference. BTIG Virtual Biotechnology Conference Date: Monday, August 9, 2021 Time: 9:30 a.m. ET H.C. Wainwright Ophthalmology Virtual Conference Date: Tuesday, August 17, 2021 Ti

Business Wire
Neutral
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
2021-07-29 08:00

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 4968588. A live webcast of the conference call will also be available on the Investors & Media page o

Zacks Investment Research
Neutral
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
2021-07-21 12:23

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

Loading more news...